EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada
- 12 September 2022
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 173, 58-66
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2017
- The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysisOncotarget, 2016
- Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium ExperienceJournal of Thoracic Oncology, 2015
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung CancerCancer Discovery, 2014
- Sample Features Associated with Success Rates in Population-Based EGFR Mutation TestingJournal of Thoracic Oncology, 2014
- Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 StudyJournal of Clinical Oncology, 2013
- Lung Cancer Biomarkers: Present Status and Future DevelopmentsArchives of Pathology & Laboratory Medicine, 2013
- Clinical Significance of IGF1R Expression in Non–Small-Cell Lung CancerClinical Lung Cancer, 2012
- Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLCLung Cancer, 2010
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008